Literature DB >> 21428895

Hybrid molecules incorporating natural products: applications in cancer therapy, neurodegenerative disorders and beyond.

M Decker1.   

Abstract

In this article the design of hybrid molecules that covalently connect two distinct drug entities in one molecule, at least one part being a biologically active natural product will be discussed. In the quest for novel drug entities, the hybrid approach is a promising path to drug molecules that can effectively target multifactorial diseases including neurodegenerative disorders like Alzheimer's and Parkinson's diseases (AD and PD). The hybrid approach can also be used to optimize certain biological properties like affinity and selectivity, but also to gain novel biological activities distinct from the ones of the components. Due to the high potential of natural products to exhibit pronounced biological activities, natural products have been one of the major sources of components in hybrid molecules. This review will cover their applications in developing drugs for neurodegenerative disorders, in the diverse field of anti-cancer agents (which represents the major application for natural products in medicinal chemistry), but also in miscellaneous areas of bioactive compounds including antioxidants, antimalarial drugs and estrogen-related hybrids to reach various therapeutic aims. The unique tasks of hybrid molecule design will be addressed, such as describing suitable ways to chemically connect the drug components, how to use the approach to enhance biological activity with respect to both activity and selectivity and potential drawbacks of the hybrid approach. It will be shown that hybrids can be more than the sum of their components, but in many cases should be considered as pharmacological entities in their own respect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21428895     DOI: 10.2174/092986711795328355

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  25 in total

1.  Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Mariem Chayah; M Encarnacion Camacho; Filippo Prencipe; Ernest Hamel; Francesca Consolaro; Giuseppe Basso; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2014-05-10       Impact factor: 6.514

2.  Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.

Authors:  Shengtao Xu; Lingling Pei; Chengqian Wang; Yun-Kai Zhang; Dahong Li; Hequan Yao; Xiaoming Wu; Zhe-Sheng Chen; Yijun Sun; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2014-05-28       Impact factor: 4.345

3.  Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer.

Authors:  Fouad H Darras; Beata Kling; Jörg Heilmann; Michael Decker
Journal:  ACS Med Chem Lett       Date:  2012-08-22       Impact factor: 4.345

4.  New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.

Authors:  Ángela P Hernández; Paula Díez; Pablo A García; José M Miguel Del Corral; Martín Pérez-Andrés; David Díez; Arturo San Feliciano; Manuel Fuentes; Ma Ángeles Castro
Journal:  ACS Med Chem Lett       Date:  2018-03-08       Impact factor: 4.345

5.  Effects of the Hybridization of Opioid and Neurotensin Pharmacophores on Cell Survival in Rat Organotypic Hippocampal Slice Cultures.

Authors:  Patrycja Kleczkowska; Maria Kawalec; Magdalena Bujalska-Zadrozny; Małgorzata Filip; Barbara Zablocka; Andrzej W Lipkowski
Journal:  Neurotox Res       Date:  2015-08-19       Impact factor: 3.911

6.  Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.

Authors:  Arun A Yadav; Xing Wu; Daywin Patel; Jack C Yalowich; Brian B Hasinoff
Journal:  Bioorg Med Chem       Date:  2014-09-16       Impact factor: 3.641

7.  Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma.

Authors:  Kai Liu; Datong Zhang; Jeremy Chojnacki; Yuhong Du; Haian Fu; Steven Grant; Shijun Zhang
Journal:  Org Biomol Chem       Date:  2013-06-20       Impact factor: 3.876

Review 8.  Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems.

Authors:  Ivana Cacciatore; Leonardo Baldassarre; Erika Fornasari; Adriano Mollica; Francesco Pinnen
Journal:  Oxid Med Cell Longev       Date:  2012-06-03       Impact factor: 6.543

9.  Gold-catalyzed oxycyclization of allenic carbamates: expeditious synthesis of 1,3-oxazin-2-ones.

Authors:  Benito Alcaide; Pedro Almendros; M Teresa Quirós; Israel Fernández
Journal:  Beilstein J Org Chem       Date:  2013-04-26       Impact factor: 2.883

10.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.

Authors:  Si-Yuan Pan; Shu-Feng Zhou; Si-Hua Gao; Zhi-Ling Yu; Shuo-Feng Zhang; Min-Ke Tang; Jian-Ning Sun; Dik-Lung Ma; Yi-Fan Han; Wang-Fun Fong; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.